Pericardial Effusion After Renal Transplantation: Timing and Clinical Characteristics

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Pericardial effusion and cardiac tamponade are known risks post-renal transplantation.
• Identifying specific medication risks is crucial for patient management.

Purpose of the Study:

• To investigate the association between sirolimus and pericardial effusion development in renal transplant recipients.
• To analyze the timing and risk factors for pericardial effusion after kidney transplantation.

Main Methods:

• Retrospective analysis of 585 renal transplant patients (2005-2016).
• 82 patients developed new-onset pericardial effusion, categorized as early (≤4 years) or late (>4 years) post-transplant.
• Logistic regression used to assess immunosuppressant use and effusion timing.

Main Results:

• Sirolimus use was more frequent in the late-onset effusion group (>4 years).
• Sirolimus therapy significantly increased the risk of late-onset pericardial effusion (aOR 3.58, P=.017) after adjusting for comorbidities.
• No significant demographic or comorbidity differences between early and late effusion groups.

Conclusions:

• Pericardial effusion is a notable complication in renal transplant recipients.
• Sirolimus is associated with an increased risk of developing late-onset pericardial effusion.
• Further research is needed to identify specific risk factors and guide clinical practice.